Praxis Precision Medicines (PRAX): One of the Best Upside Stocks

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the 9 Best Upside Stocks to Buy According to Analysts.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best upside stocks to buy according to analysts. On April 14, Praxis Precision Medicines announced that the US FDA accepted its NDA for ulixacaltamide HCl. This treatment is intended for adults living with essential tremor/ET, a central nervous system condition. The FDA has established a Prescription Drug User Fee Act/PDUFA target action date of January 29, 2027, and currently does not anticipate holding an advisory committee meeting as part of the review process.

Praxis Precision Medicines (PRAX): One of the Best Upside Stocks

Africa Studio/Shutterstock.com

The application is supported by data from the Essential3 Phase 3 program, which included two pivotal studies demonstrating statistically and clinically significant results. Throughout these trials, ulixacaltamide was generally well tolerated, maintaining a safety profile consistent with earlier research and reporting no drug-related serious adverse events. This regulatory milestone follows the FDA’s decision to grant the therapy Breakthrough Therapy Designation in December 2025.

Ulixacaltamide is a selective small molecule inhibitor designed to target T-type calcium channels to block abnormal neuronal firing associated with tremor activity. As the leading program in the company’s Cerebrum small molecule platform, it represents a precision neuroscience approach to treating ET. Praxis Precision Medicines Inc. (NASDAQ:PRAX) is now focusing on the review process and preparing for a potential commercial launch to provide a therapy developed specifically for this patient population.

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company engaging in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance.

While we acknowledge the risk and potential of PRAX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PRAX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.